Discovery of 2′,4′-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC)
- 9 April 2015
- journal article
- Published by Springer Science and Business Media LLC in Archives of Pharmacal Research
- Vol. 38 (10), 1783-1788
- https://doi.org/10.1007/s12272-015-0595-6
Abstract
Heat shock protein 90 (Hsp90) is a ATP dependent molecular chaperone and has emerged as an attractive therapeutic target in the war on cancer due to its role in regulating maturation and stabilization of numerous oncogenic proteins. In this study, we discovered that 2′,4′-dimethoxychalcone (1b) disrupted Hsp90 chaperoning function and inhibited the growth of iressa-resistant non-small cell lung cancer (NSCLC, H1975). The result suggested that 2′,4′-dimethoxychalcone (1b) could serve as a potential therapeutic lead to circumvent the drug resistance acquired by EGFR mutation and Met amplification.Keywords
This publication has 23 references indexed in Scilit:
- Targeted cancer therapiesNature Reviews Drug Discovery, 2010
- Drug Discovery and Natural Products: End of an Era or an Endless Frontier?Science, 2009
- Targeting HSP90 for cancer therapyBritish Journal of Cancer, 2009
- Kava, a Tonic for Relieving the Irrational Development of Natural Preventive AgentsCancer Prevention Research, 2008
- Development and application of Hsp90 inhibitorsDrug Discovery Today, 2008
- Tumor Selectivity of Hsp90 Inhibitors: The Explanation Remains ElusiveACS Chemical Biology, 2006
- Synthesis of chalcone analogues with increased antileishmanial activityBioorganic & Medicinal Chemistry, 2006
- Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 IsoformsCell Chemical Biology, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the ChaperoneJournal of Biological Chemistry, 2000